WCLC 2022 on Ipilimumab and Nivolumab in Pretreated Patients With Malignant Pleural Mesothelioma | VuMedi

WCLC 2022 Conference Coverage

WCLC 2022 on Ipilimumab and Nivolumab in Pretreated Patients With Malignant Pleural Mesothelioma

By WCLC 2022 Conference Coverage FEATURING Marko Jakopovic

By WCLC 2022 Conference Coverage FEATURING Marko Jakopovic

0 views

September 7, 2022

Comments 0

Login to view comments. Click here to Login